

PRESS CLIPPING SHEET

PUBLICATION:	Business Today
DATE:	September-2018
COUNTRY:	Egypt
CIRCULATION:	10,000
TITLE :	Novartis S.A.E announces FDA approval for Deferasirox.
PAGE:	63
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	1,500

Novartis S.A.E announces FDA approval for Deferasirox

In a joint press conference with the Egyptian Thalassemia Association (ETA), Novartis has announced the launch of its first to market drug, Deferasirox film coated tablets, a new oral formulation for oral suspension for the treatment of chronic iron overload; a disease that affects 5-9% of Egyptians. Dr. Mona Hamdy, Professor of Hematology and Pediatrics and Director of the Center for Clinical Research at the Faculty of Medicine, Cairo University said, "For many years, pharmaceutical companies, especially Novartis have worked consistently to discover new treatments for Thalassemia patients. Deferasirox film-coated tablet is the latest in a journey Novartis began in 1968 when it announced for the first time its revolutionary Deferoxamine treatment.

